Fennec Pharmaceuticals Reports Strong 2025 Sales Growth, Eliminates Debt, and Secures PEDMARK® Exclusivity to 2033

summarizeSummary

Fennec Pharmaceuticals reported strong 50% growth in PEDMARK® sales for 2025, successfully eliminated all outstanding debt through a significant equity offering, and secured patent exclusivity for PEDMARK® until 2033 via a litigation settlement.

check_boxKey Events

• Record PEDMARK® Sales Growth

  Net PEDMARK® product sales increased by 50% year-over-year, reaching $44.6 million for the full fiscal year 2025.

• Debt Fully Eliminated

  The company redeemed all remaining outstanding senior secured convertible notes for approximately $21.7 million in November 2025, resulting in zero debt outstanding at year-end.

• Successful Equity Offering

  Fennec completed public and private equity offerings in November 2025, raising approximately $45.275 million in gross proceeds to fund debt repayment and general corporate purposes.

• Patent Litigation Settled, Exclusivity Extended

  A settlement with Cipla Limited and Cipla USA, Inc. was reached on March 16, 2026, preventing generic sodium thiosulfate product entry until September 1, 2033, significantly extending market exclusivity for PEDMARK®.

auto_awesomeAnalysis

Fennec Pharmaceuticals' 2025 annual report highlights significant progress in commercialization and strategic positioning, despite an increase in net loss. The company achieved a 50% year-over-year increase in net PEDMARK® product sales, reaching $44.6 million. A major positive development is the full redemption of all outstanding convertible notes totaling $21.7 million in November 2025, effectively eliminating debt. This was largely funded by a successful $45.275 million gross equity offering in November 2025, which, while dilutive, secured the company's financial runway. Furthermore, the company announced a settlement agreement with Cipla on March 16, 2026, preventing generic entry of PEDMARK® until September 1, 2033, a critical win for intellectual property protection and long-term revenue stability. The company also continues to expand internationally and advance investigator-initiated studies for PEDMARK® in new patient populations. The shift to negative operating cash flow in 2025 and increased net loss reflect ongoing commercialization and R&D investments, which are now supported by a stronger, debt-free balance sheet and extended market exclusivity.